scispace - formally typeset
M

Michael D. Prados

Researcher at University of California, San Francisco

Publications -  466
Citations -  57545

Michael D. Prados is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Glioma & Temozolomide. The author has an hindex of 107, co-authored 444 publications receiving 51418 citations. Previous affiliations of Michael D. Prados include Harvard University & University of Texas at Austin.

Papers
More filters
Journal Article

Genetic aberrations defined by comparative genomic hybridization distinguish long-term from typical survivors of glioblastoma.

Eric C. Burton, +8 more
- 01 Nov 2002 - 
TL;DR: A comparison of rare LTSs with STSs (typical GBM survivors) identified 6q loss, 10q Loss, and 19q gain, particularly when two or more of these were present, as most closely associated with aggressive clinical behavior in GBM.
Journal ArticleDOI

Quality of life self-reports from 200 brain tumor patients: comparisons with Karnofsky performance scores.

Norman Mackworth, +2 more
- 01 Nov 1992 - 
TL;DR: Depression, reported by half of the patients, was not predicted by the KPS when age was excluded from the regression analysis but was related to the scores in well-being and socializing, and neither depression, well- Being, nor socializing was influenced by age.
Journal ArticleDOI

Procarbazine, Lomustine, and Vincristine (PCV) Chemotherapy for Anaplastic Astrocytoma: A Retrospective Review of Radiation Therapy Oncology Group Protocols Comparing Survival With Carmustine or PCV Adjuvant Chemotherapy

Michael D. Prados, +5 more
- 01 Nov 1999 - 
TL;DR: Using this retrospective analysis, there does not seem to be any survival benefit to PCV chemotherapy, and future phase III studies for patients with AA may need to consider whether BCNU or PCV is used in the control arm.
Journal ArticleDOI

Gemistocytic astrocytomas: a reappraisal

Hendrikus G. J. Krouwer, +3 more
- 01 Mar 1991 - 
TL;DR: The authors conclude that the presence of at least 20% gemistocytes in a glial neoplasm is a poor prognostic sign, irrespective of the pathological background, and proposes that gemistocytic astrocytomas be classified with anaplastic astroCytomas and treated accordingly.
Journal ArticleDOI

Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme.

Susan M. Chang, +9 more
- 01 Oct 2004 - 
TL;DR: This strategy of combination TMZ, thalid and RT was relatively well tolerated with favorable survival outcome for patients with GM when compared to patients not treated with adjuvant chemotherapy and similar to those who have received nitrosourea adjuant chemotherapy.